182 related articles for article (PubMed ID: 26578234)
1. Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Tardoski S; Ngo J; Gineyts E; Roux JP; Clézardin P; Melodelima D
Sci Rep; 2015 Nov; 5():16354. PubMed ID: 26578234
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
[TBL] [Abstract][Full Text] [Related]
5. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
8. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
Merrell MA; Wakchoure S; Ilvesaro JM; Zinn K; Gehrs B; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Mar; 559(1):21-31. PubMed ID: 17214981
[TBL] [Abstract][Full Text] [Related]
11. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
12. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
[TBL] [Abstract][Full Text] [Related]
13. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
16. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
18. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
Koizumi M; Nakaseko C; Ohwada C; Takeuchi M; Ozawa S; Shimizu N; Cho R; Nishimura M; Saito Y
Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213
[TBL] [Abstract][Full Text] [Related]
19. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
Misso G; Porru M; Stoppacciaro A; Castellano M; De Cicco F; Leonetti C; Santini D; Caraglia M
Cancer Biol Ther; 2012 Dec; 13(14):1491-500. PubMed ID: 22990205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
